Set - Out - English

ate

onset

hypogonadism

ADAM:

treatment

ssoc

ras

2014; 60(5):404-414

413

Recommendation

There are few studies with high levels of evidence in rela-

tion to the contraindications of testosterone replacement.

It is weakly recommendable to not use testosterone in pa-

tients with prostate or breast cancer with PSA > 4 ng/mL

or 3 ng/mL in high risk patients or those with palpable

prostate nodule, hematocrit greater than 50% or in pa-

tients with grade II or IV CHF.

eferences

Martits AM, Costa EMF. Late onset male hypogonadism or andropause.

Rev Assoc Med Bras 2004;50:358-9.

2. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et

al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation,

treatment and monitoring of late-onset hypogonadism in males. Aging

Male 2009;12:05 AM-12.

Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al.

Double-blind placebo-controlled study of testosterone patch therapy on

bone turnover in men with borderline hypogonadism. Int J Androl

2006;29:381-91.

Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE,

Oldham JA, et al. Effects of testosterone on muscle strength, physical function,

body composition, and quality of life in intermediate-frail and frail elderly

men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol

Metab 2010;95:639-50.

Sullivan DH, Roberson PK, Johnson LE, Bishara O, Evans WJ, Smith ES, et

al. Effects of muscle strength training and testosterone in frail elderly males.

Med Sci Sports Exerc 2005;37:1664-72.

6. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone

therapy prevents gain in visceral adipose tissue and loss of skeletal muscle

in nonobese aging men. J Clin Endocrinol Metab 2008;93:139-46.

Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement

therapy improves insulin resistance, glycaemic control, visceral adiposity

and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur

J Endocrinol 2006;154:899-906.

Katznelson L, Robinson MW, Coyle CL, Lee H, Farrell CE. Effects of modest

testosterone supplementation and exercise for 12 weeks on body composition

and quality of life in elderly men. Eur J Endocrinol 2006;155:867-75.

Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F.

Effects of testosterone supplementation on markers of the metabolic

syndrome and inflammation in hypogonadal men with the metabolic

syndrome: the double-blinded placebo-controlled Moscow study.

ClinEndocrinol (Oxf). 2010;73:602-12.

10. Giannoulis MG, Sonksen PH, Umpleby M, Breen L, Pentecost C, Whyte M, et

al. The effects of growth hormone and/or testosterone in healthy elderly men:

a randomized controlled trial. J Clin Endocrinol Metab 2006;91:477-84.

11.

Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin

S, et al. Testosterone and growth hormone improve body composition and

muscle performance in older men. J Clin Endocrinol Metab 2009;94:1991-

2001.

12.

Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et

al. Effects of testosterone on sexual function in men: results of a meta-

analysis. ClinEndocrinol (Oxf) 2005;63:381-94.

13. Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, et al.

Transdermal testosterone gel increases serum testosterone levels in

hypogonadal men in Taiwan with improvements in sexual function. Int J

Impot Res 2007;19:411-7.

14. Allan CA, Forbes EA, Strauss BJ, McLachlan RI. Testosterone therapy increases

sexual desire in ageing men with low-normal testosterone levels and

symptoms of androgen deficiency. Int J Impot Res 2008;20:396-401.

15.

Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann

C, et al. Comparison of long-acting testosterone undecanoate formulation

versus

testosterone enanthate on sexual function and mood in hypogonadal

men. Eur J Endocrinol 2009;160:815-9.

16.

Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects

of 12 month administration of the novel long-acting testosterone

undecanoate on measures of sexual function and the metabolic syndrome.

Arch Androl 2007;53:353-7.

17.

Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM, et

al. Oral testosterone replacement in symptomatic late-onset hypogonadism:

effects on rating scales and general safety in a randomized, placebo-controlled

study. Eur J Endocrinol 2009;160:821-31.

18.

Shamloul R, Ghanem H, Fahmy I, El-Meleigy A, Ashoor S, Elnashaar A, et

al. Testosterone therapy can enhance erectile function response to sildenafil

in patients with PADAM: a pilot study. J Sex Med 2005;2:559-64.

19.

Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A. Androgens

and sexual function: a placebo-controlled, randomized, double-blind study

of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction

and androgen deficiency. Aging Male 2009;12:104-12.

20. Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of oral

testosterone undecanoate on visuospatial cognition, mood and quality of life

in elderly men with low-normal gonadal status. Maturitas 2005;50:124-33.

21. Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with

finasteride does not improve measurements of cognition in healthy older

men with low serum testosterone. J Androl 2007;28:875-82.

22. Young LA, Neiss MB, Samuels MH, Roselli CE, Janowsky JS. Cognition is

not modified by large but temporary changes in sex hormones in men. J

Clin Endocrinol Metab 2010;95:280-8.

23. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type

2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl

2011;34( Pt1):528-40.

24.

Herzog AG, Farina EL, Drislane FW, Schomer DL, Smithson SD, Fowler

KM, et al. A comparison of anastrozole and testosterone

versus

placebo and

testosterone for treatment of sexual dysfunction in men with epilepsy and

hypogonadism. Epilepsy Behav 2010;17:264-71.

25.

Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, et al. Two

years of treatment with dehydroepiandrosterone does not improve insulin

secretion, insulin action, or postprandial glucose turnover in elderly men

or women. Diabetes 2007;56:753-66.

26.

Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical

characteristics on the prostate-specific antigen (PSA) response to testosterone

replacement therapy. Int J Impot Res 2006;18:201-5.

27.

Sarosdy MF. Testosterone replacement for hypogonadism after treatment

of early prostate cancer with brachytherapy. Cancer 2007;109:536-41.

28.

Morales A, Black AM, Emerson LE. Testosterone administration to men

with testosterone deficiency syndrome after external beam radiotherapy for

localized prostate cancer: preliminary observations. BJU Int 2009;103:62-4.

29.

Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, et al.

Testosterone replacement therapy following radical prostatectomy. J Sex

Med 2009;6:1165-70.

30.

Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone

replacement in prostate cancer survivors with hypogonadal symptoms. BJU

Int 2010;105:1397-401.

31. Coward RM, Simhan J, Carson CC 3

. Prostate-specific antigen changes

and prostate cancer in hypogonadal men treated with testosterone

replacement therapy. BJU Int 2009;103:1179-83.

32.

Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect

of testosterone replacement therapy on prostate tissue in men with late-onset

hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-61.

33.

Daniels NA, Nielson CM, Hoffman AR, Bauer DC; Osteoporotic Fractures

In Men (MrOS) Study Group. Sex hormones and the risk of incident prostate

cancer. Urology 2010;76:1034-40.

34.

Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough

serum testosterone predicts the development of polycythemia in hypogonadal

men treated for up to 21 years with subcutaneous testosterone pellets. Eur

J Endocrinol 2010;162:385-90.

35. Yamaguchi K, Ishikawa T, Chiba K, Fujisawa M. Assessment of possible

effects for testosterone replacement therapy in men with symptomatic late-

onset hypogonadism. Andrologia 2011;43:52-6.

36.

Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement

therapy improves insulin resistance, glycaemic control, visceral adiposity

and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur

J Endocrinol 2006;154:899-906.

37.

Saad F, Gooren L, Haider A, Yassin A. Effects of testosterone gel followed

by parenteral testosterone undecanoate on sexual dysfunction and on

features of the metabolic syndrome. Andrologia 2008;40:44-8.

38.

Zhuravlev VN, Frank MA, Gomzhin AI. Sexual functions of men with

obstructive sleep apnoea syndrome and hypogonadismmay improve upon

testosterone administration: a pilot study. Andrologia 2009;41:193-5.